Abad v. Bayer Corp.

531 F. Supp. 2d 957, 2008 U.S. Dist. LEXIS 7375
CourtDistrict Court, N.D. Illinois
DecidedJanuary 17, 2008
DocketNos. 93 C 7452, 04 C 1446; MDL 986.
StatusPublished
Cited by1 cases

This text of 531 F. Supp. 2d 957 (Abad v. Bayer Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abad v. Bayer Corp., 531 F. Supp. 2d 957, 2008 U.S. Dist. LEXIS 7375 (N.D. Ill. 2008).

Opinion

[958]*958MEMORANDUM OPINION

(Ruling on Argentina Forum Non Conveniens Motion)

JOHN F. GRADY, District Judge.

The plaintiffs in this multidistrict litigation are persons suffering from hemophilia who claim to have become infected with [959]*959HIV or hepatitis C as a result of using factor concentrates (blood-clotting products derived from the plasma of blood donors) manufactured by the four defendant pharmaceutical companies. The litigation is long-standing and now in its “second generation,” consisting largely of cases brought by residents of foreign countries. The history is recounted in In re Factor VIII or IX Concentrate Blood Prods. Liab. Litig., 408 F.Supp.2d 569, 570-73 (N.D.Ill.2006)(ruling on United Kingdom forum non conveniens motion).

All of the complaints in the current MDL are substantially similar. They allege that the defendants negligently allowed their factor concentrates to be contaminated by HIV and hepatitis C from infected blood donors, causing those viruses to be transmitted to the plaintiffs when they infused the concentrates. The alleged negligence consisted of using plasma from high-risk blood donors, such as homosexual men and intravenous drug users, and then failing to take available precautions, such as heat treatment, to kill any dangerous viruses during the manufacturing process. The second claim, added by these “second generation” cases, is that the defendants, after learning that their untreated concentrates could transmit the viral infections, fraudulently “dumped” untreated concentrate on foreign markets while at the same time withdrawing the untreated product from the United States market. The defendants deny all of these claims.

Almost all of the straight negligence claims brought by United States plaintiffs were settled over ten years ago, but the more recent cases brought by the foreign residents are pending before this court on defense motions to dismiss for forum non conveniens. We have dismissed the claims brought by the residents of the United Kingdom on that basis, and that decision was affirmed. In re Factor VIII or IX Concentrate Blood Prods. Litig., 484 F.3d 951 (7th Cir.2007).

The issue presently before this court is whether to dismiss for forum non conve-niens the cases brought by residents of Argentina who claim to have become infected by using one or more of the defendants’ concentrates in Argentina. Defendants assert that Argentina is a more convenient forum for the litigation of those claims.

The United Kingdom claims were referred to as the Gullone case because that was the name of the first-named plaintiff in the low-numbered case with United Kingdom plaintiffs. For convenience, we will refer to the Argentine claims as the Abad case, since that is the name of the first-named plaintiff in the low-numbered Argentine case.

A total of 880 Argentine plaintiffs have filed suit. Their claims are set forth in a number of separate complaints, each joining multiple plaintiffs. Most of the Argentine plaintiffs (855 of the 880) filed suit in Florida state court, and the defendants removed the cases to the United States District Court for the Southern District of Florida on the basis of diversity jurisdiction. Of the Florida plaintiffs, 600 allege that they were infected in Argentina. Another 17 plaintiffs infected in Argentina are included in complaints transferred here from the Northern District of California, and 2 more are plaintiffs in suits filed in this district (which we are treating as part of the MDL), making a total of 619 plaintiffs the defendants are moving to dismiss.

The Law of Forum Non Conveniens

The steps involved in a forum non con-veniens analysis are well-settled. The first step is a two-part inquiry as to whether the proposed alternative forum — here, Argentina — is available and adequate for the litigation of plaintiffs’ claims. Kamel [960]*960v. Hill-Rom Co., 108 F.3d 799, 802-03 (7th Cir.1997) (“An alternative forum is available if all parties are amenable to process and are within the forum’s jurisdiction. An alternative forum is adequate when the parties will not be deprived of all remedies or treated unfairly.”). If the alternative forum is both available and adequate, “the district court must then balance the private and public interest factors that emerge in a given case.” Id. (citations omitted).

Availability and Adequacy

Both questions are in dispute. Defendants stipulate that if we grant their motion they will subject themselves to the process of the Argentine courts so as to be within the jurisdiction of those courts. Therefore, they say, the Argentine forum is “available.” Plaintiffs respond that the Argentine courts cannot assert jurisdiction in these cases because the plaintiffs have elected to sue in the United States, and, moreover, no act or event that could establish jurisdiction occurred in Argentina.

The parties’ arguments are based upon their differing interpretations of what they agree is the governing provision of the Argentinian Code of Civil and Commercial Procedure. It reads in relevant part, in defendants’ translation from Spanish, as follows:

Except for cases of express or implied expansion of jurisdiction, where applicable, and notwithstanding any special rules contained in this Code and other laws, ... (4) In personal actions based on intentional or unintentional torts, the competent court shall be the court sitting where the event took place or the place of residence of defendant, at the election of the plaintiff.

(Decl. of Professor Atilio Aníbal Alterini, Ex. F to Defs.’ Mem. in Supp. of Mot. to Dismiss, at 4.) The plaintiffs’ translation of the provision is somewhat different. Instead of “where the event took place or the place of residence of defendant,” their translation, provided by their expert, Dr. Edgardo Rotman, is “place of the act or where the defendant is domiciled.” (Pis.’ Mem. in Opp’n to Defs.’ Mot. to Dismiss at 4.) The difference between “residence” and “domiciled” is not important, but the difference between “event” and “act” is thought by plaintiffs to be critical to their position that jurisdiction can lie only where the defendants acted, meaning where the defendants manufactured the injurious concentrates. That was in the United States, not Argentina. The defendants, on the other hand, believe that “event” is the proper translation of the Code provision and that “event” is a word that applies to the plaintiffs’ becoming infected, which occurred in Argentina.

The Spanish word used in the Code provision is “hecho,” which defendants’ expert Alterini translates as “event.” (Alter-ini Dep. at 74.) Plaintiffs’ expert Dr. Rot-man says that “hecho” is a word “which has many meanings,” but “[i]n the context of the present case the correct meaning is ‘act’ or ‘action’.” (Aff. of Edgardo Rot-man, Ex. C to Pis.’ Mem. in Opp’n, at 7 ¶ 14).

We will now discuss the parties’ experts and the reasons they give for their opinions on the issues of availability and adequacy.

The Defendants’ Experts

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Factor Viii or Ix Concentrate Blood Prods.
531 F. Supp. 2d 957 (N.D. Illinois, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
531 F. Supp. 2d 957, 2008 U.S. Dist. LEXIS 7375, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abad-v-bayer-corp-ilnd-2008.